Dr Reddys Laboratories launches Methylprednisolone Sodium Succinate in the U.S. market

5 Apr 2022 , 02:39 PM

According to IQVIA Health data, the Solu-Medrol brand and generic had U.S. sales of approximately $144 million MAT for the most recent twelve months ending in February 2022. Dr Reddys Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial, 125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.

This medication is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/ kidney/ intestinal/ lung diseases, and immune system disorders. It decreases ones immune systems response to various diseases to reduce symptoms such as swelling, pain and allergic-type reactions.

On a consolidated basis, the drug maker reported a net profit of Rs 706.50 crore in Q3 December 2021, steeply higher than 19.80 crore in Q3 December 2020. Revenue from operations rose 7.91% to Rs 5,319.70 crore in in Q3 December 2021 over Q3 December 2020.

Shares of Dr Reddys Laboratories gained 0.71% to Rs 4,347.70 on BSE. Dr. Reddys Laboratories is an integrated pharmaceutical company. It offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major markets include – USA, India, Russia & CIS countries, and Europe.

Powered by Capital Market – Live News